Business Wire

GC Aesthetics® Announces Growth and Expansion in Brazil

Share

GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.

GC Aesthetics® has been executing an ambitious journey repositioning the brand and portfolio to offer a smart, unique, and clinically proven safe range of products to meet the needs of Brazilian women and surgeons.

The Brazilian growth strategy includes 2 main pillars. First, the commercialization of all GC Aesthetics® products and solutions designed to support the best outcome for women's breast enhancement journey, before, during and after surgery. This unique portfolio not only stands out in today’s industry but is aligned with the company leadership position and growing plans evolving from Breast Implant Manufacturers to Solution Providers.

The Brazilian revenue growth of GC Aesthetics® is also linked to the ANVISA certificate (Brazilian Health Regulatory Agency) just obtained for the re-introduction of The Round Collection™ Breast Implants. This unique microtextured surface breast implant has been the preferred option by surgeons in Brazil: 99% of surveyed Plastic Surgeons consider The Round Collection™ as the trustable product in terms of safety and performance.

“According to our most recent survey, long-term proven safety & the unique type of micro texture are the 2 top reasons Brazilian Plastic Surgeons prefer The Round Collection Implants against competitors. We are beyond excited to be back in Brazil with this product and offer Surgeons and Patients, a proven long-term, safe and reliable medical device. Pre-orders of this product have exceeded what we had planned, and we are looking forward to a very bright, leading future in Brazil and in the world” – said Carlos Reis Pinto, CEO of GC Aesthetics®

“At GCA®, we are dedicated to advancing the science of medical aesthetics and delivering exceptional clinical, operational and commercial performance to be the preferred partner of surgeons and physicians worldwide, we are excited for The Round Collection™ re-entry in Brazil and are excited of presenting our brand as ONE GCA” – mentioned Ron Cosmas, CCO of GCA®.

GC Aesthetics® will be presenting the re-introduction of this product at the Jornada Paulista de Cirurgia Plástica, held from June 15th to the 18th at the WTC São Paulo, Brazil. Engineered and designed for performanceThe Round Collection™ breast implants have an unparalled long-term safety profile. The Round Collection™ by GC Aesthetics® is part of the largest European long-term clinical study for breast implants with exceptional results at 10 years and recently had data published in a one-of-a-kind 17 year patient follow-up with remarkable patient satisfaction.

About GC Aesthetics

GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.

Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.

The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fara Naomi Macias, Chief Marketing Officer
faramacias@gcaesthetics.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology27.6.2022 07:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients. The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administratio

The Group Announces the Beginning of An Open-Ended Share Repurchase Programme Of Prosus And Naspers Shares27.6.2022 06:00:00 CEST | Press release

The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin selling small numbers of ordinary shares in Tencent Holdings Limited (“Tencent”) held by the Group (“Tencent Shares”) regularly and in an orderly manner, while concurrently purchasing Prosus Shares and Naspers Shares pursuant to the Repurchase Programme, as long as the Group

The Group Announces the Beginning of an Open-Ended Share Repurchase Programme of Prosus and Naspers Shares27.6.2022 06:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INTO OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICE AND DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT. The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin sellin

EPPA : New Study Shows That Making Reusable Containers for Takeaway Obligatory Will Undermine the EU’s Environmental Goals27.6.2022 06:00:00 CEST | Press release

Obligatory reusable packaging in takeaway services would be more burdensome for the environment than continuing to use single-use paper-based packaging. This is the conclusion of a new meta-study assessment, commissioned by the European Paper Packaging Alliance and carried out by renowned engineering consultancy, Ramboll. As the European Commission prepares to propose a revision of the Packaging and Packaging Waste Directive (PPWD) with potentially far-reaching implications, the analysis, which examined 26 scientific studies, shows that reuse systems impose exclusive additional burdens to the environment when compared to single-use, related to additional washing, take-back transportation and breakage / unit loss associated with takeaway. The results show that Climate Change is by far the most affected impact category when implementing reuse in take-away services, and that reusable tableware can also have a significant impact on water use. Commenting on the meta-study assessment, Eric L

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit